DNA Image for Research.jpg

Epilepsy Foundation Vision

To create a world without epilepsy and lives free from seizures and side effects.

Our purpose is to accelerate the development of therapies for people living with epilepsy.

In 2016, we surveyed the community asking what frustrated you most about epilepsy research & care.

You spoke. We listened.

Our Response

Invest in Innovation, Next Generation Scientists, & Engagement with Stakeholders

You said: "After all these years, research seems to be slow," 2016 Community Survey

Our response: Invest in Innovation – We test new ideas and follow new research leads by:

"Our research has no boundaries. We go where the science is. Over the past ten years, we have funded research on 6 continents."

You said: "Lack of funding and research," 2016 Community Survey

Our response: Next Generation Scientists – We invest in our future by:

You said: "Not enough education and cures," 2016 Community Survey 

Our response: Engagement — Improve communications between people with epilepsy, their families, advocates, researchers, and investors.

"Since 2003, we have provided funding to half of the therapies in the epilepsy clinical pipeline."

Our Impact

  • In 2017, the Epilepsy Therapy Project is supporting the first genetic therapy (Ataluren) for epilepsy.

"Support from the Epilepsy Foundation has allowed the first trial of a genetic therapy in epilepsy."

— Orrin Devinsky, MD

  • In 2011 the Epilepsy Therapy Project supported the development of Visualase® by Medtronic. Visualase is an MRI-Guided Laser Ablation Technology for Minimally Invasive Neurosurgery to reduce the risk of open-brain surgery for people living with epilepsy.

"Aside from the funding, validation by ETP experts who vetted our project, and found it to be a worthwhile pursuit, has been a significant factor in our rapid progress and expansion into new centers."

— Ashok Gowda, PhD, Founder of Visualase, Inc — acquired by Medtronic in 2014, President & CEO BioTex, Inc.

  • In 2013, the Epilepsy Therapy Project supported the first Epidiolex® (CBD) trial by GW Pharma for Dravet and Lennox-Gastaut.

"The origin of the Epidiolex trial began with a pivotal meeting of researchers from across the US and representatives of the Epilepsy Foundation."

— Orrin Devinsky, MD

  • In 2011, the SharkTank award went to SAMiTM by HiPass Designs for developing a sleep activity monitor to detect abnormal movements in the night.

"Winning the first Epilepsy Foundation Shark Tank Competition in 2011 allowed me to transform SAMi from an expensive custom solution for us into a refined, much less costly tool for others."

— Charles W. Anderson, President HiPass Designs

  • In 2009 and 2011, the Epilepsy Therapy Project funded the development of SmartWatch by Smart Monitor. This was one of the first watches to fuse sensor, mobile, and cloud technologies with big-data analytics to create an ease of use monitoring and alert system device for people living with epilepsy.
  • In 2008, the Epilepsy Therapy Project supported the early clinical studies of Dr. Christopher De Giorgio at UCLA for testing the Monarch eTNS device, a new noninvasive nerve stimulation device, to stop seizures. Those studies paved the way for the Monarch eTNS device to obtain approval by the European Union. Currently, Monarch eTNS, by Neurosigma, is being reviewed by the FDA.

Support Us

We won't stop until there are no seizures and no side effects. Our purpose is to accelerate the development of therapies for people living with epilepsy.

Join us in achieving this goal by supporting research at the Epilepsy Foundation.

Planting Seeds for the Future

Many of today’s educators, senior investigators, and thought leaders in the study of epilepsy were supported in their early careers with financial assistance from the Epilepsy Foundation.

Talk About It Logo
Watch: Epilepsy Research

Watch celebrities and experts talk about epilepsy on TalkAboutIt.org

Epilepsy Giving Smarter Guide
Epilepsy Giving Smarter Guide

Epilepsy Giving Smarter Guide

The Epilepsy Foundation is pleased to share with you a report developed by the Milken Institute’s Center for Strategic Philanthropy that describes the barriers to epilepsy research progress and key philanthropic opportunities.

Learn about the guide and how we are addressing research barriers.